pde4 in 4

PDE4-IN-4 is a compound acting as both a potent M3 antagonist (p IC 50 = 10.2) and a PDE4 inhibitor (p IC 50 = 8.8), designed for inhalation-based treatment of pulmonary diseases.

ethyl 1-(4-aminophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 又称 EAPT，是一种有效的选择性 PDE4抑制剂，调节细胞内环腺苷酸(cAMP)水平。它已被用于多种科研应用，包括 cAMP 介导的信号转导通路的研究，并有潜力作为治疗炎症和免疫相关疾病的药物。

PDE4 inhibitor intermediate 1 is a PDE4 inhibitor synthesis intermediate.

M3/PDE4 modulator-1 (10f) 为多功能化合物，具备M3mAChR拮抗和PDE4抑制作用。于OVA大鼠模型中，M3/PDE4 modulator-1 (10-1000 nM/kg；iv) 能降低半胱氨酸嗜酸性粒细胞内流。

(Rac)-PDE4-IN-4 是 PDE4-IN-4 的消旋体混合物。PDE4-IN-4 作为一种 M3 拮抗剂（pIC50= 10.2）以及 PDE4 抑制剂（pIC50= 8.8），适用于肺部疾病的吸入研究。

PDE IV-IN-1 是一种有效的磷酸二酯酶4 (PDE4)抑制剂，具有抗炎活性，可用于治疗哮喘，慢性阻塞性肺病和其他炎症性疾病，是研究抑郁症的潜在化合物。

Oglemilast (GRC 3886) 是一种具有口服活性磷酸二酯酶 4 (PDE4) 抑制剂，对 PDE4D3 的 IC50 为 0.5 nM。Oglemilast 在体外和体内抑制肺细胞浸润，包括嗜酸性粒细胞增多和嗜中性粒细胞减少。Oglemilast 具有应用于炎症性气道疾病的潜力。

AWD 12-281 是一种选择性磷酸二酯酶 4 (PDE4) 抑制剂，具有抗炎活性和支气管扩张活性，用于研究慢性阻塞性肺疾病（COPD）。

PF-07038124 HCl 是一种具有选择性和高效性的 PDE4 抑制剂，对 PDE4B2 的 IC50 为0.5 nM。PF-07038124 HCl 抑制 IL-13、IL-4 和 IFNγ，可用于研究特应性皮炎和斑块状银屑病等皮肤疾病。

Dovramilast (CC-11050) 是一种具有口服活性的磷酸二酯酶4(PDE4)抑制剂，，可以减少促炎介质和细胞因子的产生。Dovramilast 可用于研究结核分枝杆菌感染和红斑狼疮。

PDE4-IN-22 (Compound 2e) 为一种PDE4抑制剂，IC50 测定值仅为2.4 nM。该化合物展示出了抗炎效果，并在Imiquimod 诱导的银屑病小鼠模型中显示出强大的治疗潜力，有效抑制银屑病症状。

GPD-1116 是一种口服活性的PDE4和PDE1磷酸二酯酶抑制剂，能有效减少烟雾导致的肺细胞凋亡。此化合物在多种动物疾病模型中显示出疗效，如肺气肿、急性肺损伤、慢性阻塞性肺病 (COPD)、哮喘及肺动脉高压。

Eggmanone (EGM1) 是一种有效的、选择性的磷酸二酯酶 4(PDE4)拮抗剂，对 PDE4D3 的 IC50为 72 nM。Eggmanone 对 PDE4D3 的选择性大约是其他 PDE 的 40-50 倍。Eggmanone 通过选择性拮抗 PDE4 发挥 Hh 抑制作用，导致蛋白激酶 A 激活和随后的 Hh 阻断。

O-Demethyl apremilast is an active metabolite of the phosphodiesterase 4 (PDE4) inhibitor apremilast .1It inhibits the activity of PDE4 isolated from U937 cells and LPS-induced TNF-α production in isolated human peripheral blood mononuclear cells (PBMCs; IC50s = 8.3 and 5.6 μM, respectively). O-Demethyl apremilast is also an oxidative degradation product of apremilast.2,3 1.Hoffmann, M., Kumar, G., Schafer, P., et al.Disposition, metabolism and mass balance of [14C]apremilast following oral administrationXenobiotica41(12)1063-1075(2011) 2.Lu, Y., Shen, X., Hang, T., et al.Identification and characterization of process-related substances and degradation products in apremilast: Process optimization and degradation pathway elucidationJ. Pharm. Biomed. Anal.14170-78(2017) 3.Bhole, R.P., Naksakhare, S.R., and Bonde, C.G.A stability indicating HPTLC method for apremilast and identification of degradation products using MS/MSJ. Pharm. Sci. & Res.11(5)1861-1869(2019)

LEO 39652 is a dual-soft PDE4 inhibitor with IC50s of 1.2 nM, 1.2 nM, 3.0 nM and 3.8 nM for PDE4A, PDE4B, PDE4C and PDE4D, respectively. LEO 39652 also inhibits TNF-α with an IC50 value of 6.0 nM. LEO 39652 is used for topical research of Atopic dermatitis (AD) [1]. LEO 39652 shows unbound in vitro potency when measured as LPS induced TNF-α release in human peripheral blood mononuclear cells (PBMC), incubated in serum free medium. LEO 39652 shows a relatively high binding to human serum albumin[2]. LEO 39652 is inactivated both in blood and liver (dual-soft) while stabled in the skin[1].Pharmacokinetic AnalysisLEO 39652 exhibits total clearance (rats 930, minipigs 200 and monkey 300 mL/min/kg) and ratio to total AUC (rats 4, minipigs 6 and monkey 6 %) following intravenous administration (rats 0.075, minipigs 0.5 and monkeys 2.0 mg/kg)[1]. [1]. Jens Larsen, et al. Discovery and Early Clinical Development of Isobutyl 1-[8-Methoxy-5-(1-oxo-3 H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5- a]pyridin-2-yl]cyclopropanecarboxylate (LEO 39652), a Novel Dual-Soft" PDE4 Inhibitor for Topical Treatment of Atopic Dermatitis. J Med Chem. 2020 Dec 10;63(23):14502-14521.[2]. Stefan Eirefelt

Tetomilast (OPC-6535) is a phosphodiesterase-4 (PDE4) inhibitor, potentially effective in treating inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD).

PDE4-IN-3 is a newly developed oral compound that acts as a potent inhibitor of the enzyme phosphodiesterase 4 (PDE4), displaying a high affinity for inhibition with an IC50 value of 4.2 nM.

PDE4-IN-8 (Example 5) 是磷酸二酯酶4(PDE4)的有效抑制剂。PDE4-IN-8 对 PDE4B2 的 IC50值为 0.93 nM。然而，PDE4-IN-8 对 IL13、IL4、IFNy 的抑制作用微弱，IC50值分别为 4.04 nM, 36.33 nM, 2394 nM。

PDE4-IN-11 is a potent phosphodiesterase isoenzyme 4 (PDE4) inhibitor, exhibiting remarkable bronchodilatory and anti-inflammatory characteristics. It is specifically designed for studying obstructive or inflammatory airway diseases [1] [2] [3].

(S)-(+)-Rolipram ((+)-Rolipram) 是一种 cAMP 依赖性磷酸二酯酶 4 (PDE4) 抑制剂，IC50=1100 nM。它能够抑制人单核细胞产生的肿瘤坏死因子 α (TNFα)。

AWD 12-281 is a selective phosphodiesterase 4 (PDE4) inhibitor for the treatment of lung inflammation using inhalative administration. AWD 12-281 Is Active in a New Guinea-Pig Model of Allergic Skin Inflammation Predictive of Human Skin Penetration and Suppresses Both Th1 and Th2 Cytokines in Mice. AWD 12-281 is a very promising drug candidate not only for the treatment of lung inflammation using inhalative administration but also for the treatment of atopic dermatitis.

Fenspiride-d5 is intended for use as an internal standard for the quantification of fenspiride by GC- or LC-MS. Fenspiride is an antagonist of histamine H1 receptors and a non-steroidal anti-inflammatory drug (NSAID). It inhibits histamine-induced contraction of isolated guinea pig trachea but not histamine-induced inotropy of isolated guinea pig heart. It also inhibits phosphodiesterase 4 (PDE4), PDE5, and PDE3 (IC50s = 69, ~158, and 363 µM, respectively, in isolated human bronchi derived from patients with lung cancer). It is selective for these phosphodiesterases over PDE1 and PDE2, where it provides less than 25% inhibition. Fenspiride potentiates the airway relaxant effects of isoproterenol and sodium nitroprusside indicating an effect on cAMP and cGMP phosphodiesterases, respectively. Aerosolized fenspiride (1 mg/ml) reverses bronchoconstriction induced by capsaicin and, when used at aerosolized concentrations ranging from 1-10 mg/ml, reduces cough induced by citric aci......

LEO-29102 is a potent, selective, and soft-drug phosphodiesterase 4 (PDE4) inhibitor, which may be potentially useful for treatment of dermatological diseases. LEO 29102 shows properties suitable for patient-friendly formulations giving efficient drug delivery to the skin. LEO-29102 has reached phase 2 and demonstrated clinically relevant efficacy in the treatment of atopic dermatitis.

Toddacoumalone 是一种天然PDE4 (磷酸二酯酶 4) 抑制剂，效力中等，活性分子特性不完善。具有研究银屑病等炎症性疾病潜力。